Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASHGEN-2 siRNA Gene Silencing in NASH with Genetic Risk Factors
jRCT2011220020Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of rapirosiran in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change from baseline in quantitative liver fibrosis (qFibrosis) at week 52. Started Feb 2023; status: active, not recruiting.
02
Drugs
rapirosiran
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2011220020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220020.